Sjogren's Syndrome Clinical Trial
Official title:
Topical Products to Treat Xerostomia in Primary Sjögren's Syndrome: a Double-blind Clinical Trial
Objectives: To assess the effects of topical dry mouth products (toothpaste and mouthwash)
containing olive oil, parsley oil, provitamin B5, allantoin, betaine and xylitol in Primary
Sjögren's syndrome patients with xerostomia.
Subjects and Methods: A double-blinded, placebo-controlled, randomized design where
participants were randomly assigned at baseline test or placebo products. Participants used
the products 3 times/day/28 days. The investigators used Visual Analog Scale for xerostomia
and Oral Health Impact Profile-14, baseline and after treatment, to assess the possible
improvement.
The investigators conducted a randomized double-blind placebo controlled study among
participants with Sjögren's syndrome who attended to the Oral Medicine Specialist Degree
Program at the School of Dentistry at Complutense University in Madrid. The study was
conducted in accordance to the principles of the Helsinki Declaration. This study followed
the guidelines established by the Consort Statement.
Participants. All participants had a full medical history about Primary Sjögren's syndrome,
where their rheumatologist detailed how the correct diagnosis was made according to
American-European Consensus Group 2002 criteria. Demographic and Primary Sjögren's syndrome
characteristics were collected. Stimulated and unstimulated whole saliva were collected
following the drainage method at baseline by a single trained clinician blinded to the
treatment. The saliva was collected before giving study instructions between 8-10 am.
Hyposalivation was present when unstimulated whole saliva was less than 0.1 ml/min or
stimulated whole saliva was less than 0.7 ml/min.
Preparations. The company Biocosmetics provided the test and placebo products. Placebo
preparations were in identical white bottles (250mL) and white toothpastes (50mL) like study
products. These preparations (study or placebo) did not contain irritant substances. The
placebo included the same excipients resulting in solution similar to the experimental one in
colour, flavour and density. All ingredients were equal in parts except the active products
that were only present in the study products: betaine, xylitol, allantoin, Olea Europaea
Fruit Oil (olive oil), Panthenol (provitamine B5) and Carum Petroselinum Seed oil (parsley
oil). Test and placebo products contain sodium fluoride (mouthwash 250ppmF- and toothpaste
995ppmF-).
Interventions and instructions to participants. Participants were randomized to receive study
or placebo mouthwash and toothpaste. Before starting treatment, participants were instructed
to rinse with 7mL of mouthwash (study or placebo) for 60 seconds after meals (3 times/day).
After rinsing the mouth, patients were instructed to brush their teeth with 0.5 g of study or
placebo toothpaste following the Bass brushing technique for 3 minutes. We gave all the
patients the same ultra soft dental brush (CS5460 Curaprox, Curaden AG, Kriens, Switzerland).
The products had to be used for 28 days (4 weeks). Participants were informed that the use of
any oral hygiene or xerostomia products apart from the intervention was prohibited. After
giving the instructions, the investigators gave the patients the corresponding bag containing
the study or placebo products, which was completely closed.
Sample size. The sample size was calculated considering a previous study that applied the
same products. It was estimated that, at least, 50% of the test group would improve; so with
an alpha of 0.05 and a statistical power of 80%, 12 subjects would be required in each group.
Randomisation. Participants were randomly assigned to one of treatments (study or placebo) in
a 1:1 ratio using a computer-generated algorithm stratified by using a fixed block sized of
4. The company performed the randomisation and prepared the products in opaque bags following
the results of randomization. The participants received the correspondence bag following the
sequence of study entry.
Blinding. The study and placebo products had an identical appearance and were packaged
identically. The sacs were numbered consecutively from 1 to 28. The company prepared and
numbered the bag and all the participants were blinded to the treatment. Blinding was
revealed after all participants finished the trial and all the data were collected.
Statistical methods. All the analysis was done using SPSS version 22.0 (SPSS Inc. New York,
NY, USA). Statistical analysis included basic descriptive statistics. Comparison of
continuous variables between test and placebo groups was done using Mann-Whitney U-test.
Comparison of categorical variables was done using Chi-square test or Fisher's exact test.
Wilcoxon signed-rank test was used to determine whether the intragroup decreases in Visual
Analogue Scale and Oral Health Impact Profile 14 were statistically significant. Differences
were considered significant if p was less than or equal to 0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT04968912 -
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT00809003 -
Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
|
N/A | |
Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
Completed |
NCT05005806 -
Fish Oil (Omega 3 ) in Sjogren's Syndrome
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Terminated |
NCT04143841 -
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
|
N/A | |
Recruiting |
NCT06104124 -
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
|
Phase 3 | |
Recruiting |
NCT05115487 -
Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
|
||
Recruiting |
NCT06437652 -
An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
|
||
Recruiting |
NCT05383677 -
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT03938207 -
Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
|
||
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT04546542 -
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
|
||
Recruiting |
NCT05085431 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
|
Early Phase 1 | |
Completed |
NCT00565526 -
Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
|
||
Completed |
NCT01369589 -
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
|
Phase 1/Phase 2 | |
Completed |
NCT00001953 -
The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers
|
N/A | |
Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 |